Latest News

Weight loss drug manufacturers are lining up to take advantage of a lucrative market, as the competition heats up

Weight loss drug manufacturers are lining up to take advantage of a lucrative market, as the competition heats up

Novo Nordisk, Eli Lilly, and other pharmaceutical companies are in competition for the next generation of treatments for obesity.

In recent quarters, Eli Lilly’s Zepbound gained market share against Novo’s Wegovy -- a trend that led, in part to the Friday ouster of Novo CEO Lars Fruergaard Jorgensen.

Here is a list with weight loss drugs that are being developed by Novo, Lilly, and other companies in search of the next big treatment.

NOVO NORDISK

The Danish pharmaceutical company is developing several experimental weight loss drugs. These include a pill, a new-generation injection, called amycretin and a drug called CagriSema.

In an early stage trial last year, Novo's Amycretin, taken daily, led to a 13.1% weight reduction after only 12 weeks.

Early-mid-stage trials found that the shot version of amycretin caused patients to lose 22% of weight within 36 weeks.

CagriSema - touted as the potent successor of Wegovy - showed less-than-expected results in two late-stage studies. In one trial, the drug helped overweight patients reduce their weight by 22,7%. This was below Novo's expectation of 25%.

Novo intends to submit CagriSema to regulatory approval during the first quarter 2026.

Novo also has licensing agreements for drugs that are still in the testing stage, such as the $2 billion deal it signed with China's United Laboratories to develop a drug for weight loss called "triple G" which targets three hormones.

ELI LILLY

In a late-stage study, Lilly's weight-loss drug orforglipron has helped type 2 diabetics lose nearly 8% their body weight in 40 weeks.

This compares well with Novo's injectable drug Ozempic. Ozempic at the highest dosage for diabetic patients caused them to lose 6% of their weight.

Lilly plans to submit an application for orforglipron regulatory approval by the end the year.

Lilly reported that a mid-stage study of its next generation obesity drug candidate (a weekly injection retatrutide) led to a weight loss of as much as 24.2% in 48 weeks.

Lilly signed an agreement with China's Laekna biotech last year for the development of a drug to treat obesity that helps patients to lose weight and maintain muscle.

PFIZER

Pfizer stopped developing the experimental weight loss pill danuglipron in October after a patient who was undergoing a clinical trial experienced a potential drug-induced injury to the liver that resolved when the medication was discontinued.

In March, Roche acquired the rights to Zealand Pharma’s petrelintide obesity treatment in a possible deal worth up to $5,3 billion.

Carmot Therapeutics, a Swiss pharmaceutical company, acquired CT-388, an experimental drug for obesity, as part of a $2.7 billion purchase of Carmot Therapeutics that will take place in 2023. Carmot's injection, which is administered once a week, belongs to the same category as Lilly's Mounjaro or Zepbound.

The company announced last year that the early-stage trials of a second drug candidate purchased from Carmot had yielded positive outcomes.

In a year-long, mid-stage study, Amgen's MariTide drug helped obese patients lose up to 20% of body weight.

Amgen says that MariTide late-stage research will begin before the middle of this year.

Analysts say MariTide has similar weight loss benefits to Wegovy and Zepbound but slightly more side effects.

Merck signed an agreement in December worth up to $ 2 billion to license Hansoh Pharma’s oral experimental drug for treating obesity. Merck is now a late competitor to the race to provide a weight loss pill that can replace weekly injections.

The drug HS-10535 is a GLP-1 agonist similar to Wegovy or Zepbound.

ASTRAZENECA

AstraZeneca’s experimental weight loss pill, licensed from China’s Eccogene a year earlier for up to $ 2 billion, has been found safe and tolerable during an early-stage study in November 2024.

The drugmaker has announced that it is moving the once-daily pill AZD5004 into mid-stage clinical trials.

ALTIMMUNE

Altimmune's experimental weight-loss drug pemvidutide helped reduce weight on average by 15.6% and showed weight loss continued at the end treatment.

Some patients, however, experience mild to moderate nausea and vomiting.

VIKING THERAPEUTICS

Viking Therapeutics reported last year that its experimental drug VK2735 helped patients achieve a 14.7% weight loss mean after 13 weeks in a midstage study. The study enrolled 176 obese adults with at least 1 weight-related comorbidity.

The company reported that in November, nine patients who were given the highest dose of 100 milligrams lost an average of 8.2% body weight within 28 days of an early-stage study.

ZEALAND PHARMA

A Danish biotech company, Zealand Pharma, said that a high-dose of petrelintide (its weight-loss drug-candidate) helped reduce weight on average by 8.6% in an early stage study.

In August 2024, the company announced that it would begin talks with other pharmaceutical firms in the second half this year about potential partnerships for developing and commercializing petrelintide.

Therapeutics of Structure

Structure Therapeutics reported last year that its experimental oral weight loss drug reduced weight by an average of 6.2% at the end 12 weeks in a study conducted during mid-stage.

(source: Reuters)